<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03926299</url>
  </required_header>
  <id_info>
    <org_study_id>Lichen sclerosus laser study</org_study_id>
    <nct_id>NCT03926299</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Demonstrate That the Dual Laser Therapy is Effective for the Treatment of Vulvar Lichen Sclerosus</brief_title>
  <official_title>Prospective, Randomized, Active-controlled Investigator Initiated Clinical Trial to Demonstrate That the Nd:YAG/Er:YAG Dual Laser Therapy is Effective to Treat Vulvar Lichen Sclerosus and Similar to Standard Treatment With Steroid Cream</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prof. Dr. Volker Viereck</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cantonal Hospital, Frauenfeld</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to test a new, minimally invasive dual laser technique to treat
      vulvar lichen sclerosus. Efficacy and safety of the thermal non-ablative Nd:YAG laser and the
      ablative Er:YAG laser is determined and compared to the current standard treatment with high
      dose steroids. The hypothesis is that laser therapy is effective and similar to standard
      steroid therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Lichen sclerosus (LS) is a chronic inflammatory skin disease that usually involves the
      anogenital area where it causes itching and burning pain, pain during sexual intercourse, and
      anal or genital bleeding due to fissuring of the damaged tissue. In this study a treatment
      with dual laser application combining thermal non-ablative Nd:YAG with ablative Er:YAG laser
      is used to reduce the symptoms of LS. Results will be compared to the standard therapy with
      topical steroid cream.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 15, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>randomized, active-controlled</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Lichen sclerosus score (LS score)</measure>
    <time_frame>6 months</time_frame>
    <description>Reduction (i.e. improvement) of physician administered clinical LS score (Sum score of 6 items on a scale from 0-2 (0=no, 1=weak, 2=pronounced): erosions, hyperkeratosis, fissures, agglutination, stenosis, atrophy). Possible sum score ranges from 0 (normal) to 12 (maximum symptoms present).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Vulvovaginal symptom questionnaire (VSQ)</measure>
    <time_frame>At each visit through study completion, an average of 1 year</time_frame>
    <description>21 binary questions (0=no, 1=yes) about symptoms, emotional impact, impact on quality of life, impact on sexual activity. Total possible sum score is 21.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptom strength score</measure>
    <time_frame>At each visit through study completion, an average of 1 year</time_frame>
    <description>Visual analog scale (0-10) of LS symptoms itching, burning, vulvar pain, dyspareunia. Total sum score ranges from 0 (no symptoms) to 40 (maximal symptoms).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Vulvar punch biopsy</measure>
    <time_frame>Baseline and at 6 months</time_frame>
    <description>Histological changes</description>
  </other_outcome>
  <other_outcome>
    <measure>Photo documentation of vulvar skin</measure>
    <time_frame>At each visit through study completion, an average of 1 year</time_frame>
    <description>Changes of visual appearance of vulvar skin</description>
  </other_outcome>
  <other_outcome>
    <measure>Patient satisfaction</measure>
    <time_frame>At each follow-up visit (6 months and 12 months)</time_frame>
    <description>Satisfaction of the treatment. Levels: 3 = very much better, 2 = much better, 1 = a little better, 0 = no change, -1 = a little worse, -2 = much worse, -3 = very much worse</description>
  </other_outcome>
  <other_outcome>
    <measure>Pain during treatment (for laser arm only): Visual analog scale (0-10)</measure>
    <time_frame>At each laser treatment session (baseline, 1 month, 2 months, 4 months)</time_frame>
    <description>Visual analog scale (0-10)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">66</enrollment>
  <condition>Chronic Skin Disease</condition>
  <condition>Vulvar Lichen Sclerosus</condition>
  <arm_group>
    <arm_group_label>Laser</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dual Fotona laser treatment (Nd:YAG and Er:YAG)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Topical steroid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>clobetasol propionate 0.05% cream</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>FotonaSmooth SP® Spectro laser device</intervention_name>
    <description>dual laser treatment with thermal Nd:YAG and ablative Er:YAG (Fotona medical device), 4 laser sessions 4-8 weeks apart.</description>
    <arm_group_label>Laser</arm_group_label>
    <other_name>Laser therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clobetasol propionate 0.05% ointment</intervention_name>
    <description>6 months standard treatment with topical steroid cream (high dose for the first two months, medium dose for the next two months, low dose for the last two months)</description>
    <arm_group_label>Topical steroid</arm_group_label>
    <other_name>Local steroid therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Diagnosis of vulvar lichen sclerosus

          -  Clinical LS score ≥ 4

        Exclusion criteria:

          -  Concomitant steroid, calcineurin inhibitor or any other topical or systemic treatment
             for LS

          -  &lt; 3 months since start of vaginal estrogen treatment

          -  Malignant disease as the cause of the vulval symptoms

          -  BMI &gt; 35 kg/m²

          -  Acute infection (fungal, bacterial, viral) of the vulva, vagina or bladder

          -  Presence of contraindications for the laser treatment or topical steroid treatment
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Volker Viereck, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Gynecology and Obstetrics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Volker Viereck, Prof.</last_name>
    <phone>+41 52 723 7050</phone>
    <email>volker.viereck@stgag.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cantonal Hospital Frauenfeld</name>
      <address>
        <city>Frauenfeld</city>
        <state>Thurgau</state>
        <zip>8501</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Volker Viereck, MD</last_name>
      <email>volker.viereck@stgag.ch</email>
    </contact>
    <contact_backup>
      <last_name>Marianne Gamper, PhD</last_name>
      <email>marianne.gamper@stgag.ch</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>April 18, 2019</study_first_submitted>
  <study_first_submitted_qc>April 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 24, 2019</study_first_posted>
  <last_update_submitted>July 22, 2019</last_update_submitted>
  <last_update_submitted_qc>July 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Cantonal Hospital, Frauenfeld</investigator_affiliation>
    <investigator_full_name>Prof. Dr. Volker Viereck</investigator_full_name>
    <investigator_title>Head of Urogynecology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vulvar Lichen Sclerosus</mesh_term>
    <mesh_term>Skin Diseases</mesh_term>
    <mesh_term>Lichen Sclerosus et Atrophicus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clobetasol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

